ADVM

ADVM

USD

Adverum Biotechnologies Inc. Common Stock

$4.340+0.080 (1.878%)

Preço em tempo real

Healthcare
Biotecnologia
Estados Unidos

Gráfico de preços

Loading Chart...

Métricas-chave

Métricas de mercado
Fundamentos da empresa
Estatísticas de negociação

Métricas de mercado

Abertura

$4.260

Máximo

$4.340

Mínimo

$4.260

Volume

0.19M

Fundamentos da empresa

Capitalização de mercado

95.5M

Setor

Biotecnologia

País

United States

Estatísticas de negociação

Volume médio

0.58M

Bolsa de valores

NCM

Moeda

USD

Faixa de 52 semanas

Mínimo $1.78Atual $4.340Máximo $8.18

Notícias relacionadas

PR Newswire

HALPER SADEH LLC ENCOURAGES ADVM, PLYM, RNA SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

Ver mais
HALPER SADEH LLC ENCOURAGES ADVM, PLYM, RNA SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
PR Newswire

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Adverum Biotechnologies, Inc. (NASDAQ: ADVM)

Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for...

Ver mais
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Adverum Biotechnologies, Inc. (NASDAQ: ADVM)
PR Newswire

Shareholder Alert: The Ademi Firm investigates whether Adverum Biotechnologies, Inc. is obtaining a Fair Price for its Public Shareholders

The Ademi Firm is investigating Adverum (Nasdaq: ADVM) for possible breaches of fiduciary duty and other violations of law in its transaction with...

Ver mais
Shareholder Alert: The Ademi Firm investigates whether Adverum Biotechnologies, Inc. is obtaining a Fair Price for its Public Shareholders
PR Newswire

Lilly to Acquire Adverum Biotechnologies

Eli Lilly and Company (NYSE: LLY) and Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of intravitreal gene...

Ver mais
Lilly to Acquire Adverum Biotechnologies